[{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"FB101","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Freya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"FB101","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Freya Biosciences \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Sofinnova Partners"},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"FB-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Freya Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Freya Biosciences \/ Sofinnova Partners","highestDevelopmentStatusID":"12","companyTruncated":"Freya Biosciences \/ Sofinnova Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Freya Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Freya will advance the development of its lead drug, FB-101, an investigational vaginal microbial immunotherapeutic, for infertility in women with dysbiotic vaginal microbiota.

                          Brand Name : FB-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 19, 2024

                          Lead Product(s) : FB-101

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Sofinnova Partners

                          Deal Size : $38.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Freya will advance the clinical development of its lead drug candidate, FB101, an investigational vaginal microbial immunotherapeutic, for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive te...

                          Brand Name : FB101

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 12, 2023

                          Lead Product(s) : FB101

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Sofinnova Partners

                          Deal Size : $38.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : FB101, is an investigational vaginal microbial immunotherapeutic, which is investigated for the treatment of Women with Asymptomatic Vaginal Dysbiosis.

                          Brand Name : FB101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 27, 2023

                          Lead Product(s) : FB101

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank